VPRIV
VELAGLUCERASE
What it does
Velaglucerase is a medication used to help manage certain genetic conditions affecting the metabolism of fats in the body.
Commonly used for: Gaucher's disease, Gaucher disease type 1
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: South African Health Products Regulatory Authority · fetched 2026-04-15 21:24:53 · updated 2026-09-27 04:00:49
About this medicine
Velaglucerase is a medication used to help manage certain genetic conditions affecting the metabolism of fats in the body.
What it treats
- Gaucher's disease
- Gaucher disease type 1
How it works
Velaglucerase replaces an enzyme that is missing or not working properly in people with Gaucher's disease, helping to break down fats in the body.
Who it's for
This medication is for individuals diagnosed with Gaucher's disease, particularly type 1.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: velaglucerase
Velaglucerase is a recombinant enzyme used for enzyme replacement therapy in patients with Gaucher disease, a genetic disorder resulting from the deficiency of the enzyme glucocerebrosidase. By providing a functional version of this enzyme, velaglucerase helps to reduce the accumulation of glucocerebroside in tissues, alleviating the symptoms associated with the disease.
Indications
- Gaucher disease type 1
- Gaucher disease type 3
Dosage
Children: Refer to specific guidelines based on patient condition and response; dosing may vary according to age and weight.
Adults: Refer to specific guidelines based on patient condition and response; typical dosing regimens are established based on clinical practice.
Mechanism of action
Velaglucerase is a glucocerebrosidase enzyme that catalyzes the hydrolysis of glucocerebroside into glucose and ceramide. This enzymatic activity is crucial in the lysosomal degradation of glycosphingolipids. In patients with Gaucher disease, the deficiency of this enzyme leads to the accumulation of glucocerebroside, causing various pathological manifestations. By supplementing the enzyme, velaglucerase facilitates the reduction of glucocerebroside levels in macrophages and other tissues, thus mitigating the disease's symptoms.
Pharmacodynamics
The pharmacodynamic effects of velaglucerase include the reduction of glucocerebroside levels in the blood and tissues, improvement in hematologic parameters such as hemoglobin levels and platelet counts, and alleviation of splenomegaly and hepatomegaly. The therapeutic effects are generally observed after several months of treatment, with continued improvement over time.
Pharmacokinetics
Velaglucerase is administered intravenously, with its pharmacokinetics characterized by a rapid distribution phase followed by a slower elimination phase. The enzyme has a half-life of approximately 3 to 5 hours. The clearance of velaglucerase is primarily through the liver and spleen, where it exerts its effects. Factors such as age, body weight, and the presence of antibodies against the enzyme can influence its pharmacokinetic profile.
Adverse effects
- Headache
- Nausea
- Fatigue
- Abdominal pain
- Infusion-related reactions
- Hypersensitivity reactions
Precautions
- Monitor for signs of hypersensitivity during and after infusion
- Use with caution in patients with a history of allergic reactions
- Evaluate renal function before initiation and during treatment
Pregnancy
Velaglucerase is classified as pregnancy category C. The safety of velaglucerase in pregnancy has not been established, and it should only be used if the potential benefit justifies the potential risk to the fetus.
Breast-feeding
It is not known whether velaglucerase is excreted in human milk. Caution should be exercised when administering to a nursing woman.
Storage
Store in the refrigerator at 2°C to 8°C. Do not freeze. Protect from light.
Formulations
- Intravenous infusion solution
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.